Loading...
Guest User
Welcome! Please login.
| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹1398.29 Cr |
| Fresh Issue | ₹600.31 Cr |
| Offer for Sale | ₹797.98 Cr |
| Face Value | ₹2 Per Equity Share |
| Price Band | ₹780.00-796.00 per share |
| Discount | Retail: 0.00,Employee: 78.00 |
| BSE Code | 543427 |
| NSE Code | MEDPLUS |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | Edelweiss Financial Services Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 18 shares and in multiples thereof
Incorporated in 2006, Medplus Health Services is India's second-largest pharmacy retailer in terms of the number of stores and revenue. The company offers pharmaceutical and wellness products i.e. medicines, vitamins, medical devices, test kits, and fast-moving consumer goods i.e. home and personal care products, baby care products, sanitizers, soaps, and detergents, etc. It is also the first pharmacy retailer in India to offer an omnichannel platform wherein customers can purchase products through stores, place orders over the telephone, online orders, and a Click and Pick facility.
As of June 31, 2021, the company has a strong pharmacy retail network of 2,165 stores across Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Odisha, West Bengal, and Maharashtra. In fiscal 2021, its share of the organized pharmacy retail based on revenue from operations in Chennai, Bangalore, Hyderabad, and Kolkata reported at 30%, 29%, 30%, and 22% respectively. It follows a cluster-based approach for store network expansion wherein it first opens high store density in a populated residential area within a target market. The company's warehouses are located in Bengaluru, Chennai, Hyderabad, Vijaywada, Kolkata, Pune, Bhubaneshwar, Mumbai, and Nagpur.
Competitive strengths
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Investment into our Material Subsidiary, Optival for funding working capital requirements of Optival | 467.17 |
| 2 | General corporate purposes | 105.57 |
| Period Ended | 30 Sep 2021 | 31 Mar 2021 | 31 Mar 2020 | 31 Mar 2019 |
|---|---|---|---|---|
| Assets | 1,746.49 | 1,565.66 | 1,348.70 | 958.71 |
| Total Income | 1,890.90 | 3,090.81 | 2,887.89 | 2,284.94 |
| Profit After Tax | 66.37 | 63.11 | 1.79 | 11.92 |
| EBITDA | 169.64 | 238.21 | 150.96 | 131.35 |
| NET Worth | 800.98 | 730.55 | 527.80 | 291.34 |
| Reserves and Surplus | 794.54 | 730.11 | 527.61 | 291.14 |
| Total Borrowing | 56.75 | 135.24 | 105.05 | 104.40 |
| Amount in ₹ Crore | ||||
